JP2012105650A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012105650A5 JP2012105650A5 JP2011277848A JP2011277848A JP2012105650A5 JP 2012105650 A5 JP2012105650 A5 JP 2012105650A5 JP 2011277848 A JP2011277848 A JP 2011277848A JP 2011277848 A JP2011277848 A JP 2011277848A JP 2012105650 A5 JP2012105650 A5 JP 2012105650A5
- Authority
- JP
- Japan
- Prior art keywords
- complex
- substitution
- amino acid
- a3ay
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000006467 substitution reaction Methods 0.000 claims 29
- 102220494690 Small vasohibin-binding protein_K32E_mutation Human genes 0.000 claims 18
- 102220494687 Small vasohibin-binding protein_R36E_mutation Human genes 0.000 claims 17
- 230000037431 insertion Effects 0.000 claims 11
- 238000003780 insertion Methods 0.000 claims 11
- 102220595361 Anamorsin_A34E_mutation Human genes 0.000 claims 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 125000000539 amino acid group Chemical group 0.000 claims 6
- 208000032843 Hemorrhage Diseases 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 208000034158 bleeding Diseases 0.000 claims 4
- 230000000740 bleeding effect Effects 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 238000001727 in vivo Methods 0.000 claims 4
- 229920001184 polypeptide Polymers 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 230000004988 N-glycosylation Effects 0.000 claims 3
- 108010054265 Factor VIIa Proteins 0.000 claims 2
- 108010014173 Factor X Proteins 0.000 claims 2
- 208000031220 Hemophilia Diseases 0.000 claims 2
- 208000009292 Hemophilia A Diseases 0.000 claims 2
- 229940012414 factor viia Drugs 0.000 claims 2
- 230000013595 glycosylation Effects 0.000 claims 2
- 238000006206 glycosylation reaction Methods 0.000 claims 2
- 229940099816 human factor vii Drugs 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- 230000008733 trauma Effects 0.000 claims 2
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims 1
- 206010046996 Varicose vein Diseases 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 230000035602 clotting Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002209 hydrophobic effect Effects 0.000 claims 1
- 125000005647 linker group Chemical group 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 238000002271 resection Methods 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47978003P | 2003-06-19 | 2003-06-19 | |
| US60/479,780 | 2003-06-19 | ||
| DKPA200400930 | 2004-06-15 | ||
| DKPA200400930 | 2004-06-15 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006515723A Division JP4915918B2 (ja) | 2003-06-19 | 2004-06-18 | 第ＶＩＩ因子または第ＶＩＩａ因子のＧｌａドメイン変種 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012105650A JP2012105650A (ja) | 2012-06-07 |
| JP2012105650A5 true JP2012105650A5 (enExample) | 2013-03-07 |
| JP5580283B2 JP5580283B2 (ja) | 2014-08-27 |
Family
ID=33553697
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006515723A Expired - Fee Related JP4915918B2 (ja) | 2003-06-19 | 2004-06-18 | 第ＶＩＩ因子または第ＶＩＩａ因子のＧｌａドメイン変種 |
| JP2011277848A Expired - Fee Related JP5580283B2 (ja) | 2003-06-19 | 2011-12-20 | 第ＶＩＩ因子または第ＶＩＩａ因子のＧｌａドメイン変種 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006515723A Expired - Fee Related JP4915918B2 (ja) | 2003-06-19 | 2004-06-18 | 第ＶＩＩ因子または第ＶＩＩａ因子のＧｌａドメイン変種 |
Country Status (23)
| Country | Link |
|---|---|
| US (5) | US20050164932A1 (enExample) |
| EP (1) | EP1644504B8 (enExample) |
| JP (2) | JP4915918B2 (enExample) |
| KR (1) | KR101191779B1 (enExample) |
| CN (1) | CN1839203B (enExample) |
| AT (1) | ATE458057T1 (enExample) |
| AU (2) | AU2004247799B2 (enExample) |
| BR (1) | BRPI0411650A (enExample) |
| CA (1) | CA2529828C (enExample) |
| CY (1) | CY1109984T1 (enExample) |
| DE (1) | DE602004025576D1 (enExample) |
| DK (1) | DK1644504T3 (enExample) |
| ES (1) | ES2338425T3 (enExample) |
| HR (1) | HRP20100264T1 (enExample) |
| IL (1) | IL172364A (enExample) |
| MX (1) | MXPA05013769A (enExample) |
| NZ (2) | NZ573412A (enExample) |
| PL (1) | PL1644504T3 (enExample) |
| PT (1) | PT1644504E (enExample) |
| RU (1) | RU2373282C2 (enExample) |
| SI (1) | SI1644504T1 (enExample) |
| WO (1) | WO2004111242A1 (enExample) |
| ZA (1) | ZA200600539B (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1982732A3 (en) | 2000-02-11 | 2011-06-08 | Bayer HealthCare LLC | Factor VII or VIIA-like conjugates |
| US7700733B2 (en) * | 2002-04-30 | 2010-04-20 | Bayer Healthcare Llc | Factor VII or VIIa polypeptide variants |
| DK2085470T3 (da) | 2003-03-20 | 2012-08-06 | Bayer Healthcare Llc | FVII- eller FVIIa-varianter |
| DK1644504T3 (da) | 2003-06-19 | 2010-05-25 | Bayer Healthcare Llc | Faktor VII- eller -VIIA-Gla-domænevarianter |
| BRPI0514396A2 (pt) | 2004-08-17 | 2009-05-12 | Csl Behring Gmbh | polipeptìdeos dependentes de vitamina k modificada |
| US20080188400A1 (en) * | 2005-04-26 | 2008-08-07 | Maxygen Holdings Ltd. | Methods For Treating Bleeding |
| WO2006134173A2 (en) | 2005-06-17 | 2006-12-21 | Novo Nordisk Health Care Ag | Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine |
| US7696318B2 (en) | 2005-07-13 | 2010-04-13 | Novo Nordisk Health Care Ag | Host cell protein knock-out cells for production of therapeutic proteins |
| DK1907540T3 (da) * | 2005-07-22 | 2013-03-11 | Bayer Healthcare Llc | Aktivering af faktor VII i opløsning |
| EP1924689B1 (en) | 2005-09-01 | 2014-08-13 | Novo Nordisk Health Care AG | Hydrophobic interaction chromatography purification of factor vii polypeptides |
| WO2007031559A2 (en) | 2005-09-14 | 2007-03-22 | Novo Nordisk Health Care Ag | Human coagulation factor vii polypeptides |
| WO2007149406A2 (en) * | 2006-06-19 | 2007-12-27 | Nautilus Technology Llc | Modified coagulation factor ix polypeptides and use thereof for treatment |
| ES2531934T3 (es) | 2006-09-01 | 2015-03-20 | Novo Nordisk Health Care Ag | Glicoproteínas modificadas |
| FR2910969B1 (fr) * | 2006-12-29 | 2009-02-27 | Lab Francais Du Fractionnement | Procede de mesure de la concentration de facteur viia (fviia) dans un echantillon |
| EP1952822A1 (en) * | 2007-01-26 | 2008-08-06 | Novo Nordisk A/S | Factor VII polypeptides with increased affinity to platelets |
| EP2481797A1 (en) * | 2007-04-13 | 2012-08-01 | Catalyst Biosciences, Inc. | Modified factor VII polypeptides and uses thereof |
| TWI465247B (zh) | 2008-04-11 | 2014-12-21 | Catalyst Biosciences Inc | 經修飾的因子ｖｉｉ多肽和其用途 |
| WO2010149172A2 (en) | 2009-06-24 | 2010-12-29 | Rigshospitalet | SYSTEMIC PRO-HEMOSTATIC EFFECT OF CLOTTING FACTORS IN COMBINATION WITH SYMPATHICOMIMETICS WITH AGONISTIC EFFECTS ON α-ADRENERGIC AND/OR β-ADRENERGIC RECEPTORS OF THE SYMPATHETIC NERVOUS SYSTEM, RELATED TO IMPROVED CLOT STRENGTH. |
| FR2947181B1 (fr) * | 2009-06-26 | 2012-05-04 | Lfb Biotechnologies | Composition de facteur vii |
| US12203113B2 (en) | 2009-07-09 | 2025-01-21 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
| TWI595004B (zh) | 2010-11-03 | 2017-08-11 | 介控生化科技公司 | 經修飾之第九因子多胜肽及其用途 |
| KR102047235B1 (ko) * | 2012-12-24 | 2019-11-22 | 바이엘 헬스케어 엘엘씨 | 단작용성 인자 vii 폴리펩티드 |
| JP6471385B2 (ja) * | 2013-03-15 | 2019-02-20 | グラディエーター・バイオサイエンシーズ・インコーポレイテッド | 標的化剤としてのＧｌａドメイン |
| CN104211802B (zh) * | 2013-05-29 | 2018-07-27 | 成都渊源生物科技有限公司 | 人凝血因子轻链蛋白及其应用 |
| EA201791275A1 (ru) | 2014-12-10 | 2017-12-29 | Опко Байолоджикс Лтд. | Способы получения ctp-модифицированных полипептидов длительного действия |
| JP2019515904A (ja) * | 2016-04-14 | 2019-06-13 | アイコニック セラピューティクス，インコーポレイテッド | 新血管新生に関連する障害を治療するための組成物および方法 |
| HUE064463T2 (hu) | 2016-07-11 | 2024-03-28 | Opko Biologics Ltd | Hosszantartó hatású VII. koagulációs faktor és az elõállítására vonatkozó eljárások |
| PE20201462A1 (es) | 2017-09-05 | 2020-12-17 | Gladiator Biosciences Inc | Metodo de direccionamiento de exosomas |
| WO2021030787A1 (en) | 2019-08-15 | 2021-02-18 | Catalyst Biosciences, Inc. | Modified factor vii polypeptides for subcutaneous administration and on-demand treatment |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GR860984B (en) * | 1985-04-17 | 1986-08-18 | Zymogenetics Inc | Expression of factor vii and ix activities in mammalian cells |
| ZA862768B (en) * | 1985-04-17 | 1986-12-30 | Zymogenetics Inc | Expression of factor vii and ix activities in mammalian cells |
| US5180583A (en) * | 1985-11-26 | 1993-01-19 | Hedner Ulla K E | Method for the treatment of bleeding disorders |
| US5258288A (en) * | 1986-07-25 | 1993-11-02 | Genzyme Corporation | Vector containing DNA encoding mature human protein S |
| DK323587D0 (da) | 1987-06-25 | 1987-06-25 | Novo Industri As | Protein |
| FI882746L (fi) | 1987-06-12 | 1988-12-13 | Hoechst Japan | Hybridprotein c och foerfarande foer dess framstaellning. |
| US4904584A (en) * | 1987-12-23 | 1990-02-27 | Genetics Institute, Inc. | Site-specific homogeneous modification of polypeptides |
| US5648254A (en) * | 1988-01-15 | 1997-07-15 | Zymogenetics, Inc. | Co-expression in eukaryotic cells |
| JPH0246296A (ja) | 1988-08-09 | 1990-02-15 | Hoechst Japan Ltd | 雑種プロテインｃ及びその製造方法 |
| US5218092A (en) | 1988-09-29 | 1993-06-08 | Kyowa Hakko Kogyo Co., Ltd. | Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains |
| US5041376A (en) * | 1988-12-09 | 1991-08-20 | The Board Of Regents Of The University Of Texas System | Method for identifying or shielding functional sites or epitopes of proteins that enter the exocytotic pathway of eukaryotic cells, the mutant proteins so produced and genes encoding said mutant proteins |
| US5093317A (en) * | 1989-06-05 | 1992-03-03 | Cephalon, Inc. | Treating disorders by application of insulin-like growth factor |
| US5580560A (en) * | 1989-11-13 | 1996-12-03 | Novo Nordisk A/S | Modified factor VII/VIIa |
| US5225537A (en) * | 1989-12-29 | 1993-07-06 | Zymogenetics, Inc. | Methods for producing hybrid phospholipid-binding proteins |
| DE69101634T4 (de) | 1990-01-26 | 1994-12-01 | Immuno Ag | Rekombinant hergestellte blutfaktoren, verfahren zur exprimierung besagter blutfaktoren sowie in besagtem prozess verwendeter rekombinanter vaccina-virus. |
| JP3330932B2 (ja) | 1990-01-29 | 2002-10-07 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | 抗凝固剤タンパク質 |
| US5583107A (en) | 1990-09-04 | 1996-12-10 | Cor Therapeutics, Inc. | Agents affecting thrombosis and hemostasis |
| US5531916A (en) * | 1990-10-03 | 1996-07-02 | E. I. Du Pont De Nemours And Company | Hydrofluorocarbon cleaning compositions |
| EP0785273A1 (en) * | 1990-11-26 | 1997-07-23 | Genetics Institute, Inc. | Paired basic amino acid converting enzyme and DNA sequence encoding it |
| US5817788A (en) * | 1991-02-28 | 1998-10-06 | Zymogenetics, Inc. | Modified factor VII |
| US5788965A (en) * | 1991-02-28 | 1998-08-04 | Novo Nordisk A/S | Modified factor VII |
| US5833982A (en) * | 1991-02-28 | 1998-11-10 | Zymogenetics, Inc. | Modified factor VII |
| WO1992015686A1 (en) | 1991-02-28 | 1992-09-17 | Zymogenetics, Inc. | Modified factor vii |
| US5861374A (en) * | 1991-02-28 | 1999-01-19 | Novo Nordisk A/S | Modified Factor VII |
| US5504064A (en) * | 1991-04-10 | 1996-04-02 | Oklahoma Medical Research Foundation | Treatment of bleeding with modified tissue factor in combination with an activator of FVII |
| JPH0720127A (ja) * | 1993-05-07 | 1995-01-24 | Eisai Co Ltd | 各種ｐｉｖｋａの測定方法および測定試薬 |
| AU703110B2 (en) | 1993-05-21 | 1999-03-18 | Novo Nordisk A/S | Modified factor VII |
| DE19531637A1 (de) * | 1995-08-28 | 1997-03-06 | Immuno Ag | Pharmazeutische Zusammensetzung zur Behandlung von Blutgerinnungsstörugnen, Verfahren zur Herstellung derselben und deren Verwendung |
| US5837843A (en) * | 1996-11-08 | 1998-11-17 | Oklahoma Medical Research Foundation | Modified protein C |
| AU730133B2 (en) * | 1996-11-08 | 2001-02-22 | Oklahoma Medical Research Foundation | Modified protein C and methods of use thereof |
| JP2001508783A (ja) | 1997-01-29 | 2001-07-03 | ポリマスク・ファーマシューティカルズ・パブリック・リミテッド・カンパニー | Ｐｅｇ化法 |
| JP2001511162A (ja) | 1997-02-06 | 2001-08-07 | ノボ ノルディスク アクティーゼルスカブ | 付加され、そして／又は除去された付着基を有するポリペプチド−ポリマー結合体 |
| US6475725B1 (en) * | 1997-06-20 | 2002-11-05 | Baxter Aktiengesellschaft | Recombinant cell clones having increased stability and methods of making and using the same |
| AT407255B (de) * | 1997-06-20 | 2001-02-26 | Immuno Ag | Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons |
| CN1269805A (zh) | 1997-07-14 | 2000-10-11 | 博尔德生物技术公司 | 生长激素和相关蛋白的衍生物 |
| AU8101698A (en) | 1997-07-18 | 1999-02-10 | Novo Nordisk A/S | Use of fviia or fviiai for the treatment of adverse conditions related to the fviia mediated intracellular signalling pathway |
| US6747003B1 (en) * | 1997-10-23 | 2004-06-08 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| US6017882A (en) * | 1997-10-23 | 2000-01-25 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| US7247708B2 (en) * | 1997-10-23 | 2007-07-24 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| US6693075B1 (en) | 1997-10-23 | 2004-02-17 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| AT408613B (de) | 1998-06-17 | 2002-01-25 | Immuno Ag | Pharmazeutisches faktor vii-präparat |
| ATE365210T1 (de) | 1998-10-30 | 2007-07-15 | Novozymes As | Glykosylierte proteine mit reduzierter allergenität |
| JP2003500003A (ja) | 1998-10-30 | 2003-01-07 | ノボザイムス アクティーゼルスカブ | 低いアレルゲン性のタンパク質変異型 |
| ATE408020T1 (de) | 1998-11-06 | 2008-09-15 | Novo Nordisk Healthcare Ag | Verfahren zur herstellung von faktor vii |
| AU3629800A (en) | 1999-03-16 | 2000-10-04 | Children's Hospital Of Philadelphia, The | Enhanced gamma-carboxylation of recombinant vitamin k-dependent clotting factors |
| EP1982732A3 (en) * | 2000-02-11 | 2011-06-08 | Bayer HealthCare LLC | Factor VII or VIIA-like conjugates |
| US7220837B1 (en) * | 2000-04-28 | 2007-05-22 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| AU2001254624A1 (en) | 2000-05-03 | 2001-11-12 | Novo-Nordisk A/S | Human coagulation factor vii variants |
| US7160540B2 (en) * | 2000-06-30 | 2007-01-09 | Regents Of The University Of Minnesota | Methods for detecting activity of clottings factors |
| US6423826B1 (en) | 2000-06-30 | 2002-07-23 | Regents Of The University Of Minnesota | High molecular weight derivatives of vitamin K-dependent polypeptides |
| US20030211094A1 (en) * | 2001-06-26 | 2003-11-13 | Nelsestuen Gary L. | High molecular weight derivatives of vitamin k-dependent polypeptides |
| RU2326126C2 (ru) * | 2000-09-13 | 2008-06-10 | Ново Нордиск Хелт Кэр Аг | Полипептид фактора vii свертывания крови, его получение и применение |
| HUP0301246A3 (en) | 2000-09-13 | 2005-12-28 | Novo Nordisk Healthcare Ag | Human coagulation factor vii variants |
| EP1325127B1 (en) * | 2000-10-02 | 2009-03-11 | Novo Nordisk Health Care AG | Method for the production of vitamin k-dependent proteins |
| AU2002218029A1 (en) | 2000-11-09 | 2002-05-21 | The Scripps Research Institute | Modified factor viia |
| IL157842A0 (en) | 2001-03-22 | 2004-03-28 | Novo Nordisk Healthcare Ag | Coagulation factor vii derivatives |
| ATE532858T1 (de) | 2001-09-27 | 2011-11-15 | Novo Nordisk Healthcare Ag | Menschliche gerinnungsfaktor-vii-polypeptide |
| ES2490590T3 (es) | 2001-11-02 | 2014-09-04 | Novo Nordisk Health Care Ag | Polipéptidos de factor VII de coagulación humana |
| RU2357751C2 (ru) | 2001-12-21 | 2009-06-10 | Ново Нордиск Хелт Кэр Аг | Жидкая композиция полипептидов фактора vii |
| US7700733B2 (en) * | 2002-04-30 | 2010-04-20 | Bayer Healthcare Llc | Factor VII or VIIa polypeptide variants |
| EP1549677B1 (en) | 2002-09-30 | 2011-04-13 | Bayer HealthCare LLC | FVII OR FVIIa VARIANTS HAVING INCREASED CLOTTING ACTIVITY |
| DK2085470T3 (da) * | 2003-03-20 | 2012-08-06 | Bayer Healthcare Llc | FVII- eller FVIIa-varianter |
| US20060116324A1 (en) * | 2003-06-13 | 2006-06-01 | Novo Nordisk Healthcare A/G | Novel formulations |
| DK1644504T3 (da) * | 2003-06-19 | 2010-05-25 | Bayer Healthcare Llc | Faktor VII- eller -VIIA-Gla-domænevarianter |
-
2004
- 2004-06-18 DK DK04738925.9T patent/DK1644504T3/da active
- 2004-06-18 BR BRPI0411650-0A patent/BRPI0411650A/pt not_active IP Right Cessation
- 2004-06-18 PL PL04738925T patent/PL1644504T3/pl unknown
- 2004-06-18 ES ES04738925T patent/ES2338425T3/es not_active Expired - Lifetime
- 2004-06-18 CA CA2529828A patent/CA2529828C/en not_active Expired - Fee Related
- 2004-06-18 AT AT04738925T patent/ATE458057T1/de active
- 2004-06-18 EP EP04738925A patent/EP1644504B8/en not_active Expired - Lifetime
- 2004-06-18 NZ NZ573412A patent/NZ573412A/en not_active IP Right Cessation
- 2004-06-18 MX MXPA05013769A patent/MXPA05013769A/es active IP Right Grant
- 2004-06-18 HR HR20100264T patent/HRP20100264T1/hr unknown
- 2004-06-18 KR KR1020057024386A patent/KR101191779B1/ko not_active Expired - Fee Related
- 2004-06-18 PT PT04738925T patent/PT1644504E/pt unknown
- 2004-06-18 DE DE602004025576T patent/DE602004025576D1/de not_active Expired - Lifetime
- 2004-06-18 WO PCT/DK2004/000428 patent/WO2004111242A1/en not_active Ceased
- 2004-06-18 RU RU2006101391/13A patent/RU2373282C2/ru not_active IP Right Cessation
- 2004-06-18 SI SI200431396T patent/SI1644504T1/sl unknown
- 2004-06-18 JP JP2006515723A patent/JP4915918B2/ja not_active Expired - Fee Related
- 2004-06-18 AU AU2004247799A patent/AU2004247799B2/en not_active Ceased
- 2004-06-18 NZ NZ544728A patent/NZ544728A/en unknown
- 2004-06-18 CN CN2004800237774A patent/CN1839203B/zh not_active Expired - Fee Related
- 2004-12-22 US US11/021,239 patent/US20050164932A1/en not_active Abandoned
-
2005
- 2005-12-05 IL IL172364A patent/IL172364A/en not_active IP Right Cessation
-
2006
- 2006-01-19 ZA ZA2006/00539A patent/ZA200600539B/en unknown
- 2006-04-21 US US11/379,664 patent/US20060252128A1/en not_active Abandoned
- 2006-06-14 US US11/424,035 patent/US8987202B2/en not_active Expired - Fee Related
- 2006-06-14 US US11/424,030 patent/US7807638B2/en not_active Expired - Fee Related
- 2006-12-21 US US11/643,535 patent/US20070117756A1/en not_active Abandoned
-
2010
- 2010-03-02 AU AU2010200793A patent/AU2010200793B2/en not_active Ceased
- 2010-04-23 CY CY20101100374T patent/CY1109984T1/el unknown
-
2011
- 2011-12-20 JP JP2011277848A patent/JP5580283B2/ja not_active Expired - Fee Related